Live Breaking News & Updates on Therapy Under Real World Conditions

Stay updated with breaking news from Therapy under real world conditions. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting

ABBVie will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of Hematology Annual Meeting in Atlanta, Georgia . "We are dedicated to transforming standards of care for people living with blood cancers," said Mohamed Zaki M.D., Ph.D, vice president and global head of oncology development, AbbVie. "The data we are presenting at the ASH Annual Meeting build on . ....

United States , Mohamed Zaki , Obinutuzumab Clb , Venetoclax Rituximab Ven , Janssen Biotech Inc , Abbvie Company , American Society Of Hematology , Us National Library Of Medicine , Abbvie Inc , National Comprehensive Cancer Network , Macrophage Properties Journal Of Immunology Baltimore , Outcomes Research , Exchange Commission , Development Of Novel Anti , Roche Group , American Society , Annual Meeting , Line Treatment , Plus Venetoclax , Chronic Lymphocytic Leukemia , Year Post Randomization Disease Free Survival , Results From , Minimal Residual Disease , Combination Small Molecules , Prospective Data , Versus Chlorambucil Plus Obinutuzumab ,

AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting

/PRNewswire/ AbbVie (NYSE: ABBV) will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of. ....

United States , Mohamed Zaki , Obinutuzumab Clb , Venetoclax Rituximab Ven , Janssen Biotech Inc , Abbvie Company , American Society Of Hematology , Us National Library Of Medicine , Abbvie Inc , National Comprehensive Cancer Network , Macrophage Properties Journal Of Immunology Baltimore , Outcomes Research , Exchange Commission , Development Of Novel Anti , Roche Group , American Society , Annual Meeting , Line Treatment , Plus Venetoclax , Chronic Lymphocytic Leukemia , Year Post Randomization Disease Free Survival , Results From , Minimal Residual Disease , Combination Small , Prospective Data , Versus Chlorambucil Plus Obinutuzumab ,